Can-Fite BioPharma: Rises on positive preclinical data for cannabis compound

Can Fite Biopharma

05/04/2021 12:36

** Israeli biotech co's U.S.-listed shares  CANF.N  rise
8.16% to $2.65 premarket
    ** Co says its cannabis compound inhibited liver cancer cell
growth in preclinical studies (https://refini.tv/3fJnsQr)
    ** CANF is developing treatments for diseases with an
overexpression of a cell component called A3AR, including
cancer, autoimmune, inflammatory and metabolic disorders
    ** Co has filed patent applications protecting its discovery
of cannabinoid-based therapies in liver cancer

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))